Plus   Neg

CenturyLink Reports Special Committee's Key Findings - Quick Facts

CenturyLink Inc. (CTL) announced that a Special Committee of independent board members has reported the findings of its review of the company's policies, procedures and practices relating to consumer sales, service and billing. The company said the investigation did not reveal evidence to conclude that any member of the company's management team engaged in fraud.

The company's outside directors voluntarily formed the Special Committee after a former employee alleged that the company engaged in sales-related misconduct, including charging customers for services they did not order—a practice known as cramming.

CenturyLink reported that the Special Committee's key findings include: company management did not condone or encourage cramming, and the evidence did not show that cramming was common at the company.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
In the age of social media, it takes mere hours for a company to suffer the backlash of of allegations of racism. For some companies, these incidents have hurt their bottom line and sullied their reputations. For others, they were a blip caused by clumsy if not altogether coincidental missteps. In... BJ's Wholesale Club Holdings Inc., which is planning a return to the public market, has set terms for its planned initial public offering or IPO. In a filing with the U.S. Securities and Exchange Commission, the warehouse club operator said Monday that it plans to offer 37.5 million shares priced between $15 and $17 per share. At the top end of the range, the offering would raise $637.5 million. Shares of Valeant Pharmaceuticals International Inc. are falling more than 6 percent in Monday's trading following news that the U.S. Food and Drug Administration has failed to approve the Canada-based company's Duobrii lotion for the treatment of plaque psoriasis. Ortho Dermatologics, a division of Valeant Pharmaceuticals, said it has received a Complete Response Letter or CRL from the FDA.
Follow RTT